Anthony Johnson is the founder of Goldfinch Biopharma. Goldfinch Biopharma has raised $160M in total funding. Latest round: Series B. Based in Cambridge, USA.
Anthony Johnson, M.D., was appointed president and chief executive officer of Goldfinch Bio, a company focused on precision therapies for kidney disease, in December 2017. Before joining Goldfinch Bio, he served as head of early clinical development for the Innovative Medicines and Early Development Biotech Unit at AstraZeneca and was a venture partner at OrbiMed Advisors.
Full founder directory · Investor directory · Company funding database · Fundraising library